Increased expression of A Proliferation-inducing Ligand (APRIL) in lung leukocytes and alveolar epithelial cells in COPD patients with non small cell lung cancer: a possible link between COPD and lung cancer?

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters

| Citation | Polverino, Francesca, Maria Laucho-Contreras, Joselyn Rojas Quintero, Miguel Divo, Victor Pinto-Plata, Lynette Sholl, Juan P. de-Torres, Bartolome R. Celli, and Caroline A. Owen. 2016. “Increased expression of A Proliferation-inducing Ligand (APRIL) in lung leukocytes and alveolar epithelial cells in COPD patients with non small cell lung cancer: a possible link between COPD and lung cancer?” Multidisciplinary Respiratory Medicine 11 (1): 17. doi:10.1186/s40248-016-0051-6. http://dx.doi.org/10.1186/s40248-016-0051-6. |
|--------|----------------------------------------------------------------------------------|
| Published Version | doi:10.1186/s40248-016-0051-6 |
| Citable link | http://nrs.harvard.edu/urn-3:HUL.InstRepos:26860268 |
| Terms of Use | This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http:// |
Increased expression of A Proliferation-inducing Ligand (APRIL) in lung leukocytes and alveolar epithelial cells in COPD patients with non small cell lung cancer: a possible link between COPD and lung cancer?

Francesca Polverino1,2,3†, Maria Laucho-Contreras1†, Joselyn Rojas Quintero1, Miguel Divo1,2, Victor Pinto-Plata1,2, Lynette Sholl4, Juan P. de-Torres5, Bartolome R. Celli1,2 and Caroline A. Owen1,2*  

Abstract  

Background: Chronic Obstructive Pulmonary Disease (COPD) is characterized by an excessive activation of the adaptive immune system and, in particular, uncontrolled expansion of the B-cell pool. One of the key promoters of B cell expansion is A PRoliferation-Inducing Ligand (APRIL). APRIL has been strongly linked to non small cell lung cancer (NSCLC) onset and progression previously. However, little is known about the expression of APRIL in the lungs of COPD patients.  

Methods: Using immuno-fluorescence staining, the expression of APRIL was assessed in sections of lungs from 4 subjects with primary diagnosis of COPD (FEV1 33 ± 20 % predicted), 4 subjects with primary diagnosis of NSCLC, 4 subjects diagnosed with both COPD and NSCLC, smokers without COPD or NSCLC and 3 healthy never-smokers. The percentage of B cells, alveolar macrophages (AMs) and polymorphonuclear neutrophils (PMNs) in the lung and alveolar epithelial cells (AECs) that stained positively for APRIL was quantified using epi-fluorescence microscopy and image analysis software.  

Results: The percentage of APRIL-expressing B cells, AMs, PMNs and alveolar epithelial cells (AECs) was higher in patients having both COPD and NSCLC than in patients with either COPD or NSCLC alone, SC or NSC (p < 0.03 for all comparisons). The percentage of APRIL-expressing AMs and AECs (but not in B cells) was higher in patients with NSCLC alone than in patients with COPD alone. The percentage of APRIL-expressing AECs (but not B cells or AMs) was higher in COPD patients than in SC and NSC (p < 0.05 for all comparisons). The percentage of APRIL-expressing B cells, AMs and AECs cells was similar in NSC and SC.  

(Continued on next page)
Conclusion: The percentage of APRIL-expressing B cells, AMs and AECs is higher in the lungs of patients with both COPD and NSCLC than in patients with COPD or NSCLC alone or control subjects. These findings suggest that APRIL may contribute to the pathogenesis of both COPD and NSCLC, and possibly to the development of NSCLC in patients with established COPD.

Keywords: Adaptive immunity, APRIL, Autoimmunity, COPD, Innate immunity, Non small cell lung cancer

Background
Chronic obstructive pulmonary disease (COPD) is characterized by an enhanced pulmonary and systemic inflammatory response to inhaled particles and gases, particularly those found in tobacco smoke. COPD patients have an increased risk of developing non-small cell lung cancer (NSCLC) that is independent of smoking pack-year history [1, 2]. However, the factors that promote the development of NSCLC in COPD patients are not clear. Reactive oxygen and nitrogen species (ROS and RNS) derived from both exogenous and endogenous sources drive many of the pathways in both COPD and lung cancer [3]. ROS and RNS can react directly with DNA causing DNA damage, or impair DNA repair processes [4]. Increased lung oxidative stress levels can also increase the susceptibility of COPD patients to recurrent respiratory tract infections, and drive chronic inflammation in the lungs, leading to further DNA damage and cellular injury by inducing the production of cytokines and proteinases in the lung [5]. Injury to the lungs that is induced by chronic inflammation triggers repair processes including cellular proliferation which, together with ROS and RNS-induced DNA damage, may promote tumorigenesis.

Both innate immune cells (such as PMNs and alveolar macrophages [AMs]) and adaptive immune cells (T and B lymphocytes) participate in the chronic inflammatory responses occurring in COPD lungs [6–10]. This process does not resolve after cessation of smoking, suggesting that self-perpetuating mechanism(s) (similar to those occurring in autoimmune disease [8, 11]) are involved. This autoimmune response likely involves activation of (auto-reactive) B cells [12] as the number of B cells in small airways is increased in severe and very severe COPD [13]. In contrast to COPD, there is a negative correlation between the severity of T lymphocyte infiltration in the lung and NSCLC disease progression [14–16]. As well as in COPD patients, NSCLC patients have tertiary lymphoid structures (TLS) characterized by clusters of mature dendritic cells and T cells surrounded by B cells, and all stages of B-cell differentiation are detectable in most NSCLC tumors [17]. A high density of follicular B cells correlates with long-term survival, both in patients with early-stage NSCLC and with advanced-stage NSCLC treated with chemotherapy [17]. However, IL-10-producing immunosuppressive regulatory B cells are also increased in NSCLC, and their numbers correlate directly with disease progression [18]. Thus, the roles of B cells (and their subsets) in regulating the development of NSCLC remains unclear.

Regulation of B-cell homeostasis involves two members of the TNF-alpha family: B-cell Activating Factor (BAFF) and A proliferation-inducing ligand (APRIL, TNFSF13, TRDL-1, TNF-related death ligand-1), which share two receptors (B-cell maturation antigen (BCMA) and transmembrane activator and calcium-modulator and cyclophilin ligand interactor (TACI)). A third receptor, the BAFF receptor, only binds to BAFF [19]. BAFF and APRIL are key regulators of the immune response and are produced by myeloid leukocytes, lymphocytes and epithelial cells [20–25]. BAFF and APRIL both promote peripheral B-cell survival, maturation, and differentiation and play important roles in the production of antibodies. Serum levels of BAFF and APRIL are increased in several autoimmune diseases [26, 27].

APRIL is a type II membrane protein and a soluble form is produced by several cells [28]. APRIL expression is upregulated at the transcript and protein levels in NSCLC tumor cells and stromal fibroblasts [29, 30]. High-level expression of APRIL in stromal cells was associated with impaired differentiation of stromal cells, and APRIL expression levels in tumor cells are an independent prognostic factor for 5-year survival in patients with NSCLC [30]. While some studies report that APRIL promotes the growth of some tumor cells [31], other studies report that APRIL promotes apoptosis of other tumor cell types [32, 33]. However, nothing is known about the expression of APRIL in immune cells or lung epithelial cells in NSCLC patients. Also, it is not clear whether the expression of APRIL is altered in the lungs of COPD patients or patients having both COPD and NSCLC. Herein, we sought to address these knowledge gaps by measuring APRIL expression in lung sections from patients with primary diagnosis of COPD or NSCLC, patients with both COPD and NSCLC, smokers without lung disease and never-smokers. We also identified the leukocyte subsets and lung epithelial cell types that express this molecule in these diseases.

Methods
Subjects and ethics
Lung tissue cohort characteristics
All studies conducted on human subjects were approved by the Partners Institutional Review Board. The characteristics
of the lung tissue cohort studied are shown in Fig. 1. De-
de-identified sections of lung were obtained from lung biop-
sies, or from lung explants from COPD patients provided
by NHLBI-sponsored Lung Tissue Research Consortium
(www.ltrcpublic.com), or the Department of Pathology at
Brigham and Women’s Hospital, Boston. None of the sub-
jects studied had evidence of respiratory tract infection at
the time of lung tissue sampling. Among the subjects stud-
ied, 8 subjects had a primary diagnosis of COPD (forced
expiratory volume in 1 s/forced vital capacity [FEV₁/FVC]
< 0.7), 4 subjects had a primary diagnosis of NSCLC; 3 were
healthy ever-smokers (SC), and 3 were healthy never-
smokers (NSC). Among the COPD patients, 4 had a sec-
ondary diagnosis of NSCLC.

Immunostaining of lung sections for APRIL
Formalin-fixed and paraffin-embedded sections (5 μm
thick) of peripheral lung sections from the subjects were
studied. Lung sections were deparaffinized, and antigen
(Ag) retrieval was performed by boiling the slides
immersed in 0.01 M sodium citrate and 2 mM citrate
buffer (pH 6.0) in a microwave. We used a rabbit anti-
APRIL IgG followed by goat anti-rabbit F(ab’)2 conju-
gated to Alexa-488 to identify APRIL-positive cells.
PMNs were identified by their characteristic multi-lobed
nuclei (identified by counter-staining lung sections with
4′,6-diamidino-2-phenylindole [DAPI]). AMs were de-
fined as mononuclear cells (having ample cytoplasm)
present in the alveolar spaces. Bronchial and alveolar
epithelial cells were identified in bright-field images. To
identify B cells, we immunostained the sections with a
murine anti-CD20 IgG followed by a goat anti-murine
IgG conjugated to Alexa-546. All of the antibodies (Abs)
listed were purchased from Abcam (Cambridge, MA)
and secondary antibodies were obtained from Thermo-
Fisher Scientific (Cambridge, MA). Lung sections were
also immuno-stained with appropriate isotype-matched
non-immune control antibodies. Images of the immuno-
stained lung sections were captured and analyzed using
an epi-fluorescence microscope (Leica Microsystems,
Buffalo Grove, IL).

In order to quantify APRIL expression in PMNs and B
cells, PMNs and B cells in at least 50 non-consecutive
high-magnification fields were analyzed. At least 20
AMs within the alveolar spaces were evaluated for each
patient. Results were expressed as percentage of all
AMs, PMNs and B-cells that were counted that stained
positively for APRIL. For evaluation of APRIL in AECs,
cells in the alveolar walls in 10 non-consecutive high
magnification fields were evaluated for each subject. The
area of the alveolar wall was measured using Meta-
Morph software (Molecular Devices, Sunnyvale, CA). APRIL-positive cells within the alveolar walls were
counted and the results were expressed as the number
of positive cells/pixel of alveolar wall.

Statistical analyses
Data were analyzed using one-way ANOVA tests for
continuous variables (age, FEV₁ % predicted and pack/years)
followed by pair-wise comparisons using student’s
t-tests or Mann-Whitney U tests. The Chi-square test
was used to analyze categorical variables. P < 0.05 was
considered statistically significant.
Results

Demographics
The demographic characteristics of the patients are shown in Table 1. NSC, SC, COPD patients and patients with NSCLC did not differ in their sex ratios or pack-year smoking histories. The age of the patients having both COPD and NSCLC was significantly higher than that of the patients with COPD alone. The smoking pack-year histories of the SC, patients with COPD alone or NSCLC alone were similar, and all were significantly higher than that of the NSC by design. The pack-year smoking histories were not available for patients with COPD and NSCLC. The FEV₁ as a percentage of predicted (FEV₁ % pred) was not available for the NSC and was only available for one of the four patients with both COPD and NSCLC. In the latter group, COPD was diagnosed on the basis of the presence of emphysema in high resolution computed tomography (HRCT) scans of the thorax and an FEV₁/FVC ratio < 0.7, but the FEV₁ % predicted was not available from the electronic medical records. There was a significant difference in FEV₁ % pred between COPD patients and both SC and NSC by design.

The proportion of APRIL-expressing AMs and B cells is higher in the lungs of patients with both COPD and NSCLC versus COPD alone, NSCLC alone or control subjects
APRIL expression was detected in some B cells, AECs and AMs in lung sections from all subjects studied albeit at low levels in SC and NSC. No staining was present in bronchial epithelial cells in any of the subject groups, or in lung sections stained with non-immune isotype-matched non-immune antibodies.

The percentage of APRIL-positive B cells was higher in the lung sections from patients with both COPD and NSCLC when compared to patients with COPD alone, NSCLC alone, SC and NSC (Fig. 1; p < 0.005 for all comparisons). The percentage of APRIL-positive B cells was higher in lung sections from patients with NSCLC alone than in the lungs of SC or NSC (p < 0.03 for both comparisons; Fig. 1). The percentage of APRIL-positive B cells was similar in lung sections from patients with NSCLC alone versus COPD alone; patients with COPD alone versus SC and NSC; and also SC versus NSC.

The number of APRIL-expressing AECs is higher in patients with both COPD and NSCLC versus COPD alone, NSCLC alone or control subjects

Patients with both COPD and NSCLC had a higher number of APRIL-positive AECs per area of alveolar wall than patients with either COPD alone or NSCLC alone (p < 0.03 for both comparisons; Fig. 2) or SC or NSC (p < 0.005 for both comparisons; Fig. 2). The number of APRIL-positive AECs was higher in the alveolar walls of patients with either COPD alone or NSCLC alone than in the alveolar walls of SC and NSC (p < 0.02 for all comparisons; Fig. 2). The numbers of APRIL-positive AECs were similar in the alveolar walls of SC and NSC. No staining for APRIL was detected in bronchial epithelial cells in lung sections from any of the subject group studied (data not shown).

The proportion of APRIL-expressing AMs is higher in patients with both COPD and NSCLC versus COPD alone, NSCLC alone or control subjects
The percentage of APRIL-positive AMs was higher in lung sections from patients with both COPD and NSCLC versus NSCLC alone, COPD alone, SC or NSC (Fig. 3, p < 0.003 for all comparisons). The percentage of

| Table 1 The table shows the demographic and clinical characteristics of the healthy never smokers (NSC), healthy smokers (SC) and patients with COPD alone, NSCLC alone and both COPD and NSCLC. SC were defined as subjects that were current smokers at the time of the study or had quit smoking less than 1 year before the lung samples were obtained. |
|---|---|---|---|---|---|---|
| Characteristics | NSC (n = 3) | SC (n = 3) | COPD* (n = 3) | COPD + Cancer (n = 3) | Cancer (n = 3) | P* |
| % males | 33 | 33 | 75 | 75 | 0 | NS. |
| Age (yrs) | 65 ± 22 | 63 ± 15 | 56 ± 7 | 75 ± 12 | 64 ± 9 | P = 0.03b |
| Pack-yr smoking | 33 ± 23 | 45 ± 26 | N/A | 50 ± 10 | P < 0.001 |
| FEV₁ (% of predicted) | 87 ± 11 | 33 ± 20 | 61 | 61 | P < 0.05 |

a All COPD patients had forced expiratory volume in 1 s (forced vital capacity (FEV₁)/FVC < 0.7 whereas smokers without COPD and non-smoker controls had FEV₁/FVC > 0.7
b The results for age, pack-year smoking history and FEV₁ % predicted, are expressed as mean ± SEM. The age of the patients with both COPD and NSCLC was significantly higher than that of the patients with COPD alone
| The pack-year smoking histories of the COPD patients and SC groups were significantly different from those of NSC by design (P < 0.001 for both comparisons). The pack-year smoking histories of the patients with COPD alone and NSCLC alone were significantly different from those of the SC and NSC

* The FEV₁ % predicted and the FEV₁/FVC (not shown) in the COPD group were significantly different from that of the SC and NSC by design (P < 0.05 for both comparisons)

* Statistical analyses included one-way ANOVA tests for continuous variables (age, FEV₁ % predicted and pack/years) followed by pair-wise comparisons using student’s t-tests or Mann-Whitney U tests. The Chi-square test was used to analyze categorical variables. P < 0.05 was considered statistically significant

* The FEV₁ % predicted in the group of subjects with COPD and NSCLC was available only in 1 out of 4 subjects.
APRIL-positive AMs was higher in patients with NSCLC alone than in patients with COPD alone or NSC (\( p < 0.03 \) for both comparisons; Fig. 3). The percentage of APRIL-positive AMs was similar in lung sections from patients with COPD and SC, and also in SC and NSC.

The proportion of APRIL-expressing PMNs is higher in patients with COPD and NSCLC versus COPD alone, or NSCLC alone

The percentage of APRIL-positive PMNs was higher in lung sections from patients with COPD and NSCLC than in patients with either COPD alone or NSCLC alone (Fig. 4, \( p < 0.03 \) for both comparisons). Although low-level positive staining for APRIL was detected in PMNs in lung sections from SC and NSC, we could not quantify the expression of APRIL in cells from these subjects due to the very small number of PMNs present in peripheral lung sections from these subject groups.

Discussion

We report for the first time that there are increases in numbers of APRIL-expressing leukocytes and AECs in lungs of patients with either COPD or NSCLC versus control subjects without these diseases. APRIL-expressing cells in COPD and NSCLC lungs include B cells, AMs, PMNs and AECs but not bronchial epithelial cells. Patients with both COPD and NSCLC had a higher percentage of APRIL-expressing leukocytes and AECs than patients with either disease alone. We hypothesize that increased APRIL expression in leukocytes recruited to the lung or in AECs is linked to the progression of both COPD and NSCLC, and possibly also to the development and progression of NSCLC in patients with established COPD.

APRIL expression in COPD and NSCLC

To our knowledge, APRIL has never been studied in the lungs of COPD patients. Prior studies of NSCLC report that APRIL expression is increased in tumor cells and stromal cells in the vicinity of the tumors [30]. The activities of APRIL in regulating NSCLC development and progression are unclear as APRIL promotes the proliferation of several tumor cell lines in vitro and in vivo [31] but promotes apoptosis of other tumor cell types [32, 33]. Interestingly, APRIL expression levels in NSCLC cells are an independent prognostic factor for 5-year survival in NSCLC patients [30], suggesting that APRIL expression promotes the progression of NSCLC tumors. Whether APRIL expression in leukocytes and/or AECs can serve as a prognostic marker for either COPD or NSCLC was not studied herein, but will be the focus of our future studies.

Leukocyte-derived APRIL in COPD and NSCLC

We detected impressive increases in APRIL expression in B cells, AMs and PMNs in the lungs of patients with either COPD or NSCLC and even greater increases in APRIL expression in these leukocytes in the lungs of patients with both diseases. APRIL is produced by a variety of
APRIL expression by AECs in COPD and NSCLC

Normal bronchial epithelial cells and BEAS2B cell lines express APRIL at low levels in vitro and expression increases when cells are incubated with double stranded RNA [24], but APRIL expression by AECs has not been reported previously. Surprisingly, our study reports that AECs (but not bronchial epithelial cells) in normal lungs have detectable (albeit low-level) APRIL expression. A greater proportion of AECs (but not bronchial epithelial cells) in patients with either COPD or NSCLC patients express APRIL, and patients with both diseases had the highest proportion of APRIL-expressing AECs. APRIL is expressed in epithelial cells in other organs and may contribute to pathologies occurring in other diseases. For example, human intestinal epithelial cells trigger IgA2 class switching in B cells recruited to mucosal follicles by releasing APRIL after sensing bacteria through Toll-like receptors [42]. Thus, it is possible that APRIL expressed in the lungs of patients with COPD and NSCLC contributes to the progression of each disease by activating B cells and macrophages in the lungs (and/or tumor cells in the case of patients with NSCLC). Whether APRIL regulates the activities of AECs (such as maintenance of the lung structure, barrier function and secretion of pro-inflammatory or pro-angiogenic cytokines, growth factors and host defense proteins) [43–47] that could contribute to the progression of COPD or NSCLC is not clear.

Linking APRIL to the development of NSCLC in COPD patients

Herein, we report for the first time that APRIL expression was significantly higher in lung leukocytes and AECs in patients having both COPD and NSCLC, than in patients with either COPD alone or NSCLC alone. A common link between COPD and NSCLC is the presence of chronic pulmonary inflammation consisting of cells of both innate and adaptive immune systems, as aberrant inflammation has been proposed as the common link between these two pathologies [48]. There is substantial evidence that chronic pulmonary inflammation promotes the development and progression of COPD [25, 49, 50]. In NSCLC, there is a marked infiltration of cells of both innate and adaptive immune system, and the cell types and their tissue localization are significantly associated with progression and survival. As is the case in COPD patients, NSCLC patients have tertiary lymphoid structures (TLS) characterized by clusters of mature dendritic cells and T cells surrounded by B cells [13, 17]. Leukocytes have both tumor-promoting and -inhibiting roles [51, 52]. Although we detected increases in APRIL expression in PMNs and AMs in patients with NSCLC, the activities of APRIL in regulating PMN and AM function (such as their activation states,
survival and ability to removed transformed cells) were not examined in our study, but will be the focus of future studies. However, our results raise the intriguing possibility that increased APRIL expression in lung leukocytes in COPD patients further activates these cells to produce more APRIL. This, in turn, could create an environment conducive to tumorigenesis as reactive oxygen species released by leukocytes promote formation of reactive carbonyls that are not only tumorigenic by initiating DNA damage [53], but can directly alter the function of regulatory proteins involved in host immunity and having tumor suppressor functions [54]. Leukocytes also release various growth factors and pro-angiogenic mediators that promote tumor development [55]. Alternatively, the increased APRIL expression by AECs in COPD lungs could promote tumorigenesis by inducing excessive proliferation of bronchial epithelial cells. Once NSCLC is established in COPD lungs, the high levels of APRIL produced by leukocytes, AECs, and/or tumor cells themselves could promote NSCLC progression as APRIL potently promotes survival of tumor cells in vitro, and also when human tumors are transplanted into immune-deficient mice [31].

Limitations of our study
Our study has several limitations. First, we studied a small number of subjects. Patients with both COPD and lung cancer were significantly older than those with COPD alone. Second, in the group of patients with both COPD and NSCLC, only one out of four patients had PFT values available, and the pack-year smoking histories were not available for this group. In the latter group COPD was diagnosed using HRCT scans and FEV₁/FVC ratios < 0.7 (but the absolute FEV₁ and FVC values were not reported). Thus, we were not able to correlate APRIL expression with COPD severity, pack-year smoking history, current versus former smoker status or NSCLC cell type. Another limitation of our study is that we did not measure the APRIL expression levels per cell (only the percentage of APRIL-expressing cells). We also did not correlate APRIL expression with readouts of cellular functions germane to COPD or NSCLC. These studies will be the focus of future studies in our laboratory.

Conclusions
Herein, we report an increased APRIL expression in lung leukocytes and AECs in patients with COPD alone and NSCLC alone, and even greater increases in these cells in patients with both diseases. Our results suggest that exaggerated APRIL expression in lung leukocytes and/or AECs could create an environment conducive to the development and/or progression of NSCLC in patients with COPD.

Competing interests
The authors declare that they have no competing interests; except Bartolome R. Celli who declares competing interests with GlaxoSmithKline, Boehringer Ingelheim, Astra Zeneca, Novartis, Almirall, and Medimmune.

Authors’ contributions
All of the authors read and approved the manuscript.

Acknowledgements
This work was supported by Public Health Service, National Heart, Lung and Blood Institute Grants HL063137, HL086814, HL111935, P01 HL105339, P01 HL114501, All11475-01, R21ES025379 and RO1 HL127200, and The Flight Attendants Medical Research Institute grants CIA123066 and YFEL141004, and the Brigham and Women’s Hospital-Lovelace Respiratory Research Institute Consortium.

Author details
1Division of Pulmonary and Critical Care Medicine, Brigham and Women’s Hospital and Harvard Medical School, Room 855B, Harvard Institutes of Medicine Building, 77 Avenue Louis Pasteur, Boston, MA 02115, USA. 2Lovelace Respiratory Research Institute, Albuquerque, NM, USA. 3University of Parma, Parma, Italy. 4Department of Pathology, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA. 5Clinica Universidad de Navarra, Pamplona, Spain.

Received: 21 January 2016 Accepted: 17 February 2016
Published online: 04 April 2016

References
1. Dillon SR, Harder B, Lewis KB, Moore MD, Liu H, Bukowski TR, et al. B-lymphocyte stimulator/a proliferation-inducing ligand heterotrimers are elevated in the sera of patients with autoimmune disease and are neutralized by atackcept and B-cell maturation antigen-immunoglobulin. Arthritis Res Ther. 2010;12(2):248.
2. Young RP, Hopkins RJ, Christmas T, Black PN, Metcalf P, Gambling GD. COPD prevalence is increased in lung cancer, independent of age, sex and smoking history. Eur Respir J. 2009;34(2):380–6.
3. Durham AL, Adcock IM. The relationship between COPD and lung cancer. Lung Cancer. 2015;90(2):127–34.
4. Cooke MS, Evans MD, Dzdaroglu M, Luncz J. Oxidative DNA damage: mechanisms, mutation, and disease. FASEB J. 2003;17(10):1195–214.
5. Owen CA. Proteinases and oxidants as targets in the treatment of chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2005;2(4):373–85.
6. Saetta M, Di SA, Turato G, Facchini FM, Corbino L, Mape CE, et al. CD8+ T-lymphocytes in peripheral airways of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;157(3 Pt 1):822–6.
7. Ciof MG, Guersassimov A. Chronic obstructive pulmonary disease. Inflammation of small airways and lung parenchyma. Am J Respir Crit Care Med. 1999;160(5 Pt 2):521–5.
8. van der Strate BW, Postma DS, Brandsma CA, Melgert BN, Luinge MA, Geerlings M, et al. Cigarette smoke-induced emphysema: A role for the B cell? Am J Respir Crit Care Med. 2006;173(7):751–8.
9. Hogg JC, Chu F, Utsakaparav S, Woods R, Elliott WM, Buzatu L, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med. 2004;350(26):2645–53.
10. Polverino F, Doyle-Eisele M, McDonald J, Wilder JA, Royer C, Laucho-Contreras M, et al. A novel nonhuman primate model of cigarette smoke-induced airway disease. Am J Pathol. 2015;185(3):741–55.
11. Simmons MS, Connett JE, Nides MA, Lindgren PG, Kleeup EC, Murray RP, et al. Smoking reduction and the rate of decline in FEV(1): results from the Lung Health Study. Eur Respir J. 2005;25(6):1011–7.
12. Agusti A, Macnee W, Donaldson K, Crosio M. Hypothesis: does COPD have an autoimmune component? Thorax. 2003;58(10):832–4.
13. Polverino F, Ciosi Bc, Pons J, Laucro-Contreras M, Tejera P, Iglesias A, et al. B Cell-Activating Factor. An Orchestrator of Lymphoid Follicles in Severe Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2015;192(6):6965–705.
14. Wauters E, Janssens W, Vansteenkiste J, Decaluwe H, Heulens N, Thiempont B, et al. DNA methylation profiling of non-small cell lung cancer reveals a COPD-driven immune-related signature. Thorax. 2015;70(12):1113–22.
et al. Multidisciplinary Respiratory Medicine

Polverino F, Baraldo S, Bazzan E, Agostini S, Turato G, Lunardi F, et al. A new insight into adaptive immunity in chronic obstructive pulmonary disease: B cell activating factor belonging to the tumor necrosis factor family. J Immunol. 2006;177(10):7164–72.

Polverino F, Baraldo S, Bazzan E, Agostini S, Turato G, Lunardi F, et al. A novel insight into adaptive immunity in chronic obstructive pulmonary disease: B cell activating factor belonging to the tumor necrosis family. Am J Respir Crit Care Med. 2010;182(9):1011–9.

Chu VT, Enghard P, Riemekasten G, Berek C. In vitro and in vivo activation induces BAFF and APRIL expression in B cells. J Immunol. 2007;179(5):5947–57.

Kato A, Truong- Tran AQ, Scott AL, Matsumoto K, Schleier RP. Airway epithelial cells produce B cell-activating factor of TNF family by an IFN-beta-dependent mechanism. J Immunol. 2006;177(10):7164–72.

Polverino F, Baraldo S, Bazzan E, Agostini S, Turato G, Lunardi F, et al. A novel insight into adaptive immunity in chronic obstructive pulmonary disease: B cell activating factor belonging to the tumor necrosis factor family. J Immunol. 2006;177(10):7164–72.

Chu VT, Enghard P, Schurer S, Steinhauser G, Rudolph B, Riemekasten G, et al. Systemic activation of the immune system induces aberrant BAFF and APRIL expression in B cells in patients with systemic lupus erythematosus. Arthritis Rheum. 2009;60(7):2083–93.

Jonsson MV, Szodoray PJ, Jellett SD, Jonsson R, Skarstein K. Association between circulating levels of the novel TNF family members APRIL and BAFF and lymphoid organization in primary Sjogren’s syndrome. J Clin Immunol. 2005;25(3):189–201.

Matsuda Y, Haneda M, Kadomatsu K, Kobayashi T. A proliferation-inducing ligand convertase. EMBO Rep. 2001;2(10):945–50.

Cytokine. 2008;44(1):44.

Qian Z, Qingshan C, Chun J, Huijun Z, Feng L, Qiang W, et al. High expression of TNFSF13 in tumor cells and fibroblasts is associated with poor prognosis in non-small cell lung carcinoma Patients. Hum Immunol. 2015. doi: 10.1016/j.humimm.2015.10.015. [Epub ahead of print].

Sawicka-Powierza J, Jablonska E, Kloczko J, Piszcz J, Garley M, Ratajczk-Wrona S. Biological activation of APRIL is increased in B cell-lymphocytic leukemia. Neoplasma. 2011;58(1):45–50.

Roth W, Wagenknecht B, Klumpp A, Naumann U, Hahn M, Bodmer JL, et al. BAFF and APRIL expression in B cells in patients with systemic lupus erythematosus. Arthritis Rheum. 2009;60(7):2083–93.

Submit your next manuscript to BioMed Central and we will help you at every step:

• We accept pre-submission inquiries
• Our selector tool helps you to find the most relevant journal
• We provide round the clock customer support
• Convenient online submission
• We provide rounds to the round the clock customer support
• We provide rounds to the round the clock customer support
• We provide rounds to the round the clock customer support
• We provide rounds to the round the clock customer support

Visit www.biomedcentral.com/submit